You are here

  • Home
  • Archive
  • Volume 72, Issue 5
  • eLetter: Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors by M Genovese

Article Text

Article menu
Download PDFPDF
Electronic pages
Correspondence response
eLetter: Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors by M Genovese
  1. Areti Triantafyllou,
  2. Athina Pyrpasopoulou,
  3. Panagiota Anyfanti,
  4. Ekaterini Balaska,
  5. Spyros Aslanidis,
  6. Stella Douma
  1. Correspondence to Dr Athina Pyrpasopoulou, 2nd Prop Department of Internal Medicine, Hippokration GH, Konstantinoupoleos 49, Thessaloniki 54642, Greece; a.pyrpasopoulou{at}doctors.org.uk

https://doi.org/10.1136/annrheumdis-2013-203240

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the article by Genovese et al1 on the effect of the B-cell activating factor (BAFF) antagonist tabalumab in rheumatoid arthritis patients with inadequate response to tumour necrosis factor (TNF)a blockade. The results of this study indicated a moderate effect of tabalumab early (week 6/week 9) after initiation of therapy, both in terms of clinical as well as laboratory markers of disease activity, which however was not significantly sustained later on in the course of treatment (week 16).

    In the previous decade, biological therapies that target the B cell have become established in the treatment of rheumatoid …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.